In a pair of related studies, a team of Yale researchers has found a way to reverse type-2 diabetes and liver fibrosis in mice, and has shown that the underlying processes are conserved in humans.
The studies appear in the Feb. 4 edition of Cell Reports and in the Jan. 17 edition of Nature Communications.
In the earlier study, researchers found an important connection between how the body responds to fasting and type-2 diabetes. Fasting “switches on” a process in the body in which two particular proteins, TET3 and HNF4a, increase in the liver, driving up production of blood glucose. In type-2 diabetes, this “switch” fails to turn off when fasting ends, as it would in a non-diabetic person.
Researchers hypothesized that if they could “knock down” the levels of these two proteins, they could stop diabetes from developing. Yingqun Huang, M.D., Yale associate professor in Obstetrics, Gynecology, and Reproductive Sciences and her team injected mice with genetic material known as small interfering RNAs (siRNAs) packaged inside viruses that targeted TET3 or HNF4a. They found that blood glucose and insulin dropped significantly — effectively stopping diabetes in its tracks.
In the Feb. 4 Cell Reports study, researchers looked at how TET3 contributed to the development of fibrosis in the liver, and found that the protein was involved in fibrosis on multiple levels. Almost all fibrosis, regardless of the organ involved, starts from abnormal protein signaling, Huang said.
She and colleagues discovered that TET3 plays a role in the fibrosis signaling pathway in three different locations — and acts as an important regulator in fibrosis development. This means there are likely opportunities to develop drugs that inhibit TET3 to slow or reverse fibrosis, said Da Li, associate research scientist in genetics and co-author on both studies.
Both diseases — type-2 diabetes and fibrosis of the liver and other organs — are common, but have few treatment options. Around 28 million people in the U.S. have type-2 diabetes, characterized by high blood sugar levels, a condition that can lead to many other health problems, including heart disease, stroke, and kidney failure.
Cirrhosis is one of the leading causes of death worldwide and is marked by liver fibrosis — a buildup of scar tissue on the liver, said co-author James Boyer, M.D., professor and emeritus director of the Yale Liver Center.
Researchers noted that several drugs, such as metformin, are currently available to control blood sugar levels in patients with diabetes. But these have a range of unpleasant side effects, and patients can develop resistance to these drugs.
And there is little medical relief for fibrosis sufferers.
“Right now, there are no effective drugs for the treatment of fibrosis,” said Xuchen Zhang, M.D., associate professor in pathology and co-author on the fibrosis study.
Huang has filed for a patent related to her discoveries with support from the Yale Office of Cooperative Research.
The next step, she said, will be to identify where to best target TET3 and HNF4a and to develop the most effective siRNAs or small molecules to treat type-2 diabetes or fibrosis.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Reversing type-2 diabetes and liver fibrosis
- Lung problems ‘should now be seen as complication of type 2 diabetes’
The findings back up previous studies showing that lung conditions, such as fibrosis, restrictive lung disease (where the lungs cannot hold the usual capacity of air) and pneumonia are more common in ...
- Merck (MRK) Q1 2024 Earnings Call Transcript
Merck (NYSE: MRK) Q1 2024 Earnings Call Apr 25, 2024, 9:00 a.m. ET Thank you for standing by. Welcome to the Merck & Co. Q1 sales and earnings conference call. [Operator instructions] This call is ...
- One in five young people unknowingly live with ‘silent but deadly’ disease – are you one of them?
ONE in five young adults in show evidence of fatty liver disease, scientists say. The disease is characterised by a buildup of fat in the liver caused by alcohol or obesity, usually affecting ...
- Lack of sleep could be a factor in a 'silent epidemic,' experts warn
Lack of sleep can lead to what some experts call the “silent epidemic" — a little-known condition called non-alcoholic fatty liver disease. Here's what experts want you to know.
- Providing Access to Rezdiffra for NASH and the Therapies to Come | AMCP 2024
The pipeline for NASH treatments is robust, with six therapies in phase 3 development. Speakers at the annual AMCP meeting discuss Rezdiffra, the first drug approved specifically for NASH, and how to ...
Go deeper with Google Headlines on:
Reversing type-2 diabetes and liver fibrosis
[google_news title=”” keyword=”reversing type-2 diabetes and liver fibrosis” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Type-2 diabetes and liver fibrosis
- Lung problems ‘should now be seen as complication of type 2 diabetes’
The findings back up previous studies showing that lung conditions, such as fibrosis, restrictive lung disease (where the lungs cannot hold the usual capacity of air) and pneumonia are more common in ...
- Boehringer Ingelheim Reports Strong Growth In 2023 And Accelerates Late-Stage Pipeline - Middle East Business News And Information
Boehringer Ingelheim in India, Middle East, Turkey and Africa (IMETA) region achieved net sales of EUR 779 million, reflecting a 13% increa ...
- Q1 2024 Viking Therapeutics Inc Earnings Call
Welcome to the Viking Therapeutics First Quarter 2024 financial results conference call. (Operator Instructions) As a reminder, this conference call is being recorded today, April 24, 2024. I would ...
- Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Results From Phase 2 VENTURE ... and fibrosis. As we've previously reported, this study successfully achieved its primary endpoint after 12 weeks of ...
- Type 2 diabetes is not one-size-fits-all: Subtypes affect complications and treatment options
You may have heard of Ozempic, the "miracle drug" for weight loss, but did you know that it was actually designed as a new treatment to manage diabetes? In Canada, diabetes affects approximately 10% ...
Go deeper with Google Headlines on:
Type-2 diabetes and liver fibrosis
[google_news title=”” keyword=”type-2 diabetes and liver fibrosis” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]